

16-Sep-26				
Time	DAY1	Title	Lecturer	Moderator
9:20-9:30	Opening	Opening remarks	Mr.Eiji Watanabe (PDA Japan Chapter)	
Session A: Development of Dosage Forms and Formulations Corresponding to Modalities				
9:30-10:10	A-1	Next-generation prefilled syringes that achieve higher volume, higher viscosity, and co-administration formulations	Dr.Mitsuru Takahashi (Nippon Becton Dickinson)	Mr.Yusuke Hyakkan (Takeda Pharmaceutical Co.ltd.)
10:10-10:50	A-2	Optimizing injectability of high-viscosity biologics in next-generation syringe-based autoinjectors	Mr.Norbert Jung (Ypsomed) Mr. Alessandro Morandotti (Stevanato Group)	Mr.Yusuke Hyakkan (Takeda Pharmaceutical Co.ltd.)
10:50-11:05	Exhibitors' presentations		Half of exhibitors	
11:15-11:45	Exhibition break			
11:45-12:25	A-3	Designing Drug Delivery Systems for Context:Case Studies in Lyophilized Drug Delivery and Microliter-Scale Dose Delivery	Mr. Markus Bauss (SHL Medical) &Mr. Nils Ronquist (SHL Medical)	Mr.Yusuke Hyakkan (Takeda Pharmaceutical Co.ltd.)
12:30-13:10	Lunch (luncheon seminar)		Company : Vetter	
13:10-13:40	Exhibition break			
Session B Educational Lecture (The Global Landscape of the Healthcare Environment and the Diversifying Modalities)				
13:40-14:40	B-1	"The Future is Delivery" —How the Modality Revolution Is Transforming CMC and Medical Devices—	Mr. Norikazu EIKI (Eiki Consultants)	Ms. Michiyo Morikawa(CM Plus)
Session C: Development of Dosage Forms and Formulations Corresponding to Modalities-2				
14:40-15:20	C-1	Design Considerations for Next Generation Delivery of Oligonucleotide Therapeutics - Focus on High Concentration SC Formulations and Direct CNS Administration (IT admin.) -	Ms. Fumiko Koizumi, Dr. Tomoya Takenaka (Takeda Pharmaceutical Co. Ltd.)	Dr.Shiuhei Mieda (Daiichi Sankyo Co.Ltd.)
15:20-15:35	Exhibitors' presentations		Half of exhibitors	
15:35-16:05	Exhibition break			
16:05-16:45	C-2	Development of a Subcutaneous Drug Product for Lecanemab	Ms. Naomi Sakuramoto (Eisai Co. Ltd.)	Dr.Shiuhei Mieda (Daiichi Sankyo Co.Ltd.)
16:45-17:25	C-3	Formulation–Device Integration in Inhaled Drug Delivery: Optimizing Delivery for Respiratory Medicines	Dr. Mireia Puig-Sellart (Phillips Medisize)	Dr.Shiuhei Mieda (Daiichi Sankyo Co.Ltd.)
Session D: Container Materials and Regulatory Compliance				
17:25-18:05	D-1	Elastomer Components and the Latest Regulatory Expectations: Meeting Global Standards (Pre-recorded lectures)	Dr. Ana Kuschel (West Pharmaceutical Services)	Ms. Brigitte Reutter-Haerle (Vetter Pharma)
18:15-20:15	Mixer			

17-Sep-26				
Time	DAY2	Title	Lecturer	Moderator
Session E: Usability and Risk Management				
9:00-9:40	E-1	Usability Engineering Standard for Medical Devices (JIS T 62366-1) and its Application to Autoinjectors	Dr. Miyuki Shimizu (Medical Lab Partners)	Mr. Eiji Watanabe(PDA Japan Chapter)
9:40-10:20	E-2	Human Factors/Usability Engineering for Combination Products from a vendor's perspective	Dr. Ong Weiling (INTAGE Healthcare Inc.)	Mr. Shuichi Hatano (Shionogi & Co., Ltd.)
10:20-10:50	Exhibition break			
10:50-11:30	E-3	Risk Management in Drug-Device Combination Products in Clinical Setting	Mr. Yasunori Nagano (Sanraku Hospital)	Mr. Shuichi Hatano (Shionogi & Co., Ltd.)
Session F: Utilizing IoT (Electronic Information)				
11:30-12:10	F-1	Smart Self-Injection: Enhancing Clinical Trial Efficiency and Commercial Care Coordination	Dr. Stefanie Seiler (YPSOMED)	Mr. Kazuhisa Matsunaga (Astellas Pharma)
12:15-12:55	Lunch (luncheon seminar)		Company : I.M.A. Industria Macchine Automatiche S.p.A.	
12:55-13:25	Exhibition break			
13:25-14:05	F-2	Toward the Implementation of Safe Medication Administration	Ms. Eriko Nemoto (Terumo)	Mr. Kazuhisa Matsunaga (Astellas Pharma)
SessionG: Process Design Methods				
14:05-14:45	G-1	From Clinical Manufacturing to Commercial Supply – Key Considerations and Lessons Learned	Dr. Armin Wilfinger (Vetter Pharma)	Mr. Hiroaki Suzuki(Vetter Pharma)
14:45-15:15	Exhibition break			
15:15-15:55	G-2	Approaches to yield improvement in redundant filtration system	Mr. Taichi Hanada (Merck)	Mr. Hiroaki Suzuki(Vetter Pharma)
SessionH: Case Studies on Material Properties and Container Closer Integrity Testing				
15:55-16:35	H-1	Considerations for the Use of COC Cartridges in Combination Products for Emerging Drug Modalities	Mr. Christoph Zauner (Schott Pharma)	Mr. Yoshiya Minakami (Chugai pharmaceutical)
16:35-17:15	H-2	CCIT Strategies and Solutions for Combination Products	Dr. Wenliang Chen (Packaging Technologies & Inspection)	Mr. Yoshiya Minakami (Chugai pharmaceutical)
Session I: Q&A session				
17:20-17:50	I-1	Q&A session	Mr. Eiji Watanabe (PDA Japan Chapter)	
17:50-18:00	Closing	Closing message	Mr. Eiji Watanabe (PDA Japan Chapter)	